AP 472
Alternative Names: AP-472; Glu4 PAM AP-472Latest Information Update: 10 Nov 2021
At a glance
- Originator Vanderbilt University
- Developer Appello Pharmaceuticals; Vanderbilt University
- Class Antiparkinsonians; Small molecules
- Mechanism of Action Metabotropic glutamate receptor 4 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Parkinson's disease